Status:
TERMINATED
A Study of the Safety and Effects of ADH-1 Given Daily to Subjects With Solid Tumors
Lead Sponsor:
Adherex Technologies, Inc.
Conditions:
Neoplasms
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and ...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Signed written informed consent
- Male and female patients \> or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists
- Clinically or radiologically documented measurable disease.
- Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue
- Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG)
- Exclusion criteria:
- Receipt of ADH-1 prior to this clinical study
- Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry
- History of primary brain tumors or brain metastases
- History of spinal cord compression or tumors that have shown any evidence of active bleeding within 30 days before study entry.
- Stroke, major surgery, or other major tissue injury within 30 days before study entry
- History of congestive heart failure, myocardial infarction, angina, life threatening arrhythmias, significant electrocardiogram (ECG) abnormalities, or known hypercoagulable states
Exclusion
Key Trial Info
Start Date :
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00225550
Last Update
August 6 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030